The multiple myeloma clinic nurse’s communication challenge
Multiple myeloma is a disease that generates predictable patient confusion at almost every stage of management, because the clinical decisions that define good myeloma care are often the decisions that feel least intuitive to the patient living through them. Watching a monoclonal protein for years and then suddenly treating it aggressively. Declaring remission and then immediately starting a maintenance drug. Infusing a bone medication every month in a patient who has never fractured. Each of these decisions is grounded in trial evidence and mechanistic understanding that the myeloma clinic nurse carries in detail. Each of them is also, from the patient’s perspective, a discontinuity — something that does not fit the model of how illness and treatment should work that patients bring from every other medical experience they have had.
For Spanish-speaking patients navigating a myeloma diagnosis, these conceptual gaps are amplified by the additional layer of health literacy translation: the scientific vocabulary of myeloma management (MGUS, smoldering, M-protein, free light chains, CRAB criteria, complete response, MRD, zoledronic acid, MRONJ) does not have familiar Spanish equivalents that carry the same intuitive meaning. The myeloma clinic nurse is not just translating words. She is translating the conceptual framework of a disease that most patients — in any language — did not know existed before their diagnosis.
Three conversations that recur with Spanish-speaking patients across the myeloma clinic:
Scenario 1: Beatriz Salcedo-Flores — 58, retired hotel housekeeper from El Paso, Texas
Beatriz Salcedo-Flores is fifty-eight years old, a retired hotel housekeeper from El Paso who worked the early morning shift for twenty-two years until her knees became too painful to continue. She was diagnosed with MGUS four years ago when her primary care physician ordered a complete metabolic panel and noticed her total protein was mildly elevated and ordered a serum protein electrophoresis. She remembers the appointment when her doctor told her she had an “abnormal protein” in her blood and that they would “keep an eye on it.” She had asked whether it was cancer. He had said that it was not cancer but that it needed to be monitored. She went home and looked it up.
“MGUS,” she told her daughter that night. “Significa significáncia incierta — ni siquiera saben qué significa.” (MGUS. It means undetermined significance — they do not even know what it means.)
For two years she came for her blood draws every six months, watched the numbers, and was told to continue monitoring. Two years ago the M-protein had increased from 1.4 to 2.3 grams per deciliter, the plasma cell percentage on a new bone marrow biopsy had risen to 18 percent, and one of the immunoglobulins that should be normal — her IgA — had fallen below the normal range. She was told she now had smoldering multiple myeloma. She was told the monitoring would be every three months. She was told it still did not require treatment.
“Todavía no,” she repeated to her daughter. (Not yet.) She had held those words for two years.
This morning, myeloma clinic nurse Ana Guerrero-Castillo called her back after reviewing the results that had just come in: her M-protein was now 3.8 grams per deciliter, her free light chain ratio was 34, the bone marrow biopsy showed 38 percent plasma cells, and the skeletal survey had identified two lytic lesions in the thoracic vertebrae — T6 and T9 — that had not been there eighteen months ago. The hematologist had reviewed the results before the appointment and had written a note ordering VRd: bortezomib, lenalidomide, and dexamethasone.
Beatriz sat in the exam room with her daughter María when Ana came in. She had the MGUS pamphlet from her first appointment in her purse. She took it out and put it on the table.
“Me dijeron por cuatro años que esto no necesitaba tratamiento,” she said quietly. “Que la protéina estaba ahí pero que no era suficientemente seria para medicamentos. Ahora de repente son tres medicamentos fuertes. ¿Qué cambió?” (They told me for four years that this did not need treatment. That the protein was there but was not serious enough for medication. Now suddenly it is three strong medications. What changed?)
María added: “¿Por qué no la trataron antes? Si la protéina estaba ahí hace cuatro años, ¿no hubiera sido mejor tratarla entonces?” (Why wasn’t she treated before? If the protein was there four years ago, wouldn’t it have been better to treat it then?)
Ana recognized that both questions were coherent and fair. She did not redirect them. She sat down and opened the lab results on the screen so they could see the numbers.
“Voy a explicarles cómo funciona esto, porque tiene mucho sentido que eso se les pregunte,” she said. “El MGUS, el mieloma latente, y el mieloma activo no son tres enfermedades diferentes. Son el mismo tipo de célula — la célula plasmática que produce la protéina anormal — en tres etapas distintas.” (I am going to explain how this works, because it makes perfect sense to ask that. MGUS, smoldering myeloma, and active myeloma are not three different diseases. They are the same type of cell — the plasma cell that produces the abnormal protein — at three distinct stages.)
She explained the spectrum. In MGUS, the number of malignant plasma cells in the bone marrow is small — less than 10 percent. The M-protein they produce is present and measurable but low. At that level of cell burden, the plasma cells are not yet causing damage to the organs that myeloma damages: the kidneys, the bones, the blood. The studies that have evaluated whether treating MGUS reduces the risk of progression to active myeloma have not shown benefit — the treatment’s toxicity at that stage outweighs the disease’s impact, because at MGUS the disease is not yet causing harm. Watching was not complacency. Watching was the evidence-based management for the level of disease Beatriz had four years ago.
“La protéina que producían esas células hace cuatro años era la misma protéina que produce ahora,” Ana said. “No cambió qué está haciendo el cuerpo — cambió cuánto lo está haciendo. Con el tiempo, esas células plasmáticas aumentaron en número y empezaron a afectar a los huesos. Los estudios de imagen que hicimos hoy muestran que hay dos áreas en la columna vertebral donde el hueso se está debilitando porque las células plasmáticas activaron un proceso que destruye el hueso más rápido de lo que el cuerpo lo reconstruye. Eso es lo que define el mieloma activo: no cuánta protéina hay, sino si las células están causando daño a los órganos.” (The protein those cells produced four years ago was the same protein they produce now. What the body is doing did not change — how much of it the body is doing changed. Over time, those plasma cells increased in number and began to affect the bones. The imaging studies we did today show there are two areas in the spine where bone is being weakened because the plasma cells activated a process that destroys bone faster than the body can rebuild it. That is what defines active myeloma: not how much protein there is, but whether the cells are causing damage to organs.)
María pressed: “¿Pero si hubieran tratado antes, antes de que dañara los huesos, no hubiera sido mejor?” (But if it had been treated before, before it damaged the bones, wouldn’t it have been better?)
“Esa es exactamente la pregunta que los investigadores se han hecho, y es la que motivaron varios ensayos clínicos,” Ana said. “Los estudios que han tratado a pacientes en etapa de MGUS y de mieloma latente de bajo riesgo no han podido mostrar que tratar en esa etapa mejore los resultados. Hay estudios en mieloma latente de alto riesgo — que son pacientes con características especiales que tienen un riesgo mucho más alto de progresión rápida — que están explorando si el tratamiento temprano ayuda. Pero para la mayoría de las personas en la etapa de MGUS o mieloma latente de bajo riesgo, el seguimiento sin tratamiento es lo correcto dado lo que los estudios han encontrado, porque los efectos secundarios de la quimioterapia son reales, y tratar antes de que haya beneficio produce daño sin ganar nada.” (That is exactly the question researchers have asked themselves, and it is what motivated several clinical trials. Studies that have treated patients at the MGUS and low-risk smoldering myeloma stages have not been able to show that treating at that stage improves outcomes. There are studies in high-risk smoldering myeloma — which are patients with special characteristics that have a much higher risk of rapid progression — that are exploring whether early treatment helps. But for most people at the MGUS or low-risk smoldering myeloma stage, follow-up without treatment is the correct approach given what studies have found, because chemotherapy side effects are real, and treating before there is benefit causes harm without gaining anything.)
Beatriz had been listening carefully. She picked up the MGUS pamphlet and folded it. “¿Entonces los cuatro años de seguimiento estuvieron bien?” (So the four years of monitoring were correct?)
“Sí,” Ana said. “No solo estuvieron bien — eran lo correcto para lo que tenía entonces. Y la vigilancia frecuente que hicimos detectó el cambio en el momento en que el tratamiento pasa a ser necesario y útil. Ese es exactamente el propsito del seguimiento.” (Yes. Not just correct — they were the right thing for what you had at that time. And the frequent surveillance we did detected the change at the moment when treatment becomes necessary and useful. That is exactly the purpose of the monitoring.)
Beatriz nodded. She asked about the bones in the spine. Ana explained what lytic lesions are — areas where the bone has been resorbed faster than it can be rebuilt, creating focal weaknesses — and that the zoledronic acid she would receive alongside VRd would slow that process. She explained that the spine lesions at T6 and T9 were currently asymptomatic and stable but that they needed to be tracked. She asked whether she had any back pain she had attributed to her old work. Beatriz mentioned that yes, her upper back had ached for about four months, and she had thought it was from carrying grocery bags. Ana noted this in the chart as symptom onset predating diagnosis.
“El dolor en la espalda que tenía — puede que haya estado relacionado,” Ana said gently. “No siempre el mieloma avisa claramente. Eso es parte de por qué el seguimiento que habíamos hecho era importante — detectó el cambio antes de que el dolor fuera severo.” (The back pain you had — it may have been related. Myeloma does not always give a clear warning. That is part of why the monitoring we had done was important — it detected the change before the pain became severe.)
Scenario 2: Carlos Mendoza-Hidalgo — 70, retired construction foreman from San Diego, California
Carlos Mendoza-Hidalgo is seventy years old, a retired construction site foreman from Chula Vista who spent forty years managing crews and has the hands to show for it. He was diagnosed with IgG lambda multiple myeloma twenty-two months ago after presenting to his primary care physician with back pain, fatigue, and an incidental finding of a total protein of 9.4 grams per deciliter on routine labs. His serum protein electrophoresis showed a large M-spike at 4.8 grams per deciliter. His bone marrow biopsy confirmed 55 percent plasma cells. He had two lytic lesions in the lumbar spine.
He had started VRd immediately. He remembers the first infusion day clearly — he had brought a rosary and a thermos of coffee, and his wife Consuelo had sat with him for six hours. He had responded well. After four cycles his M-protein had dropped to 0.9 grams per deciliter. He had undergone autologous stem cell transplant at a large academic center in San Diego. At day 100 post-transplant, his serum immunofixation was negative. His serum free light chain ratio was normal. His bone marrow biopsy showed zero percent plasma cells by standard flow cytometry.
“No hay nada,” his oncologist had said. “Respuesta completa estricta.” (There is nothing. Stringent complete response.)
He was started on lenalidomide maintenance — fifteen milligrams daily for twenty-one days of every twenty-eight-day cycle. Now, eighteen months post-transplant, he sits in the myeloma clinic for his monthly visit. His labs continue to show no detectable M-protein. His bone marrow from three months ago continues to show no plasma cells. He is fatigued by the lenalidomide — not severely, but the daily pill is a reminder every morning that something is still not right.
He puts his question to myeloma clinic nurse Maria Elena Rosas-Fuentes directly, as he does most things.
“Enfermera, yo necesito que me explique una cosa,” he says. “Me hacen una biopsia de médula ósea: cero. Me hacen los análisis de sangre: nada. Hace dieciocho meses que no tienen nada. El doctor me dice respuesta completa estricta. ¿Por qué sigo tomando la pastilla todos los días?” (Nurse, I need you to explain something to me. They do a bone marrow biopsy: zero. They do the blood tests: nothing. For eighteen months they have found nothing. The doctor tells me stringent complete response. Why do I keep taking the pill every day?)
María Elena had heard this question many times. She sat down across from him.
“Le voy a explicar dos cosas: qué significa ‘nada’ en los análisis del mieloma, y cómo funciona el medicamento que está tomando. Porque las dos cosas juntas explican por qué el medicamento es más útil ahora que cuando había mucho mieloma.” (I am going to explain two things: what ‘nothing’ means in myeloma tests, and how the medication you are taking works. Because the two things together explain why the medication is most useful now, when there is the least myeloma.)
She began with detection limits. The serum immunofixation electrophoresis — the most sensitive standard test for M-protein — detects M-protein at concentrations above approximately 150 to 200 milligrams per deciliter. Standard multicolor flow cytometry for bone marrow plasma cells can detect clonal plasma cells at a sensitivity of approximately one in ten thousand to one in one hundred thousand bone marrow mononuclear cells. When Carlos is “stringent complete response” by these criteria, it means his M-protein is below 150 milligrams per deciliter and his clonal plasma cells are below one in ten thousand. It does not mean there are none.
“Hay pruebas más sensibles — se llaman pruebas de enfermedad residual mínima — que pueden detectar una célula del mieloma entre un millón de células normales de la médula ósea,” she said. “En muchos pacientes que están en respuesta completa estricta por los criterios estándar, esas pruebas todavía encuentran células residuales. No sabemos exactamente cuántas quedan en usted — no le hemos hecho esa prueba aún. Lo que sí sabemos es que el mieloma tiene una tendencia natural a volver con el tiempo incluso en los pacientes que tienen la mejor respuesta posible, porque las células que quedan — aunque sean pocas — pueden crecer de nuevo.” (There are more sensitive tests — they are called minimal residual disease tests — that can detect one myeloma cell among one million normal bone marrow cells. In many patients who are in stringent complete response by standard criteria, those tests still find residual cells. We do not know exactly how many remain in you — we have not done that test yet. What we do know is that myeloma has a natural tendency to return over time even in patients who have the best possible response, because the cells that remain — even if few — can grow again.)
Carlos listened. “¿Y el medicamento los mata?” (And the medication kills them?)
“El medicamento no los mata directamente — hace algo más sofisticado. La lenalidomida se une a una proteína dentro de las células inmunes — se llama cereblon — y eso activa una cadena de reacciones que hace que las células del sistema inmune que reconocen y atacan el mieloma sean más activas y más efectivas. En particular, activa a las células asesinas naturales — las NK cells — y a los linfocitos T citotóxicos que van y destruyen las células del mieloma que encuentran. Y reduce las células del sistema inmune que inhiben esa vigilancia.” (The medication does not kill them directly — it does something more sophisticated. Lenalidomide binds to a protein inside immune cells — it is called cereblon — and that activates a chain of reactions that makes the immune system cells that recognize and attack myeloma more active and more effective. In particular, it activates natural killer cells — NK cells — and cytotoxic T lymphocytes that go and destroy the myeloma cells they find. And it reduces the immune system cells that inhibit that surveillance.)
“¿Y eso es mejor cuando hay poco mieloma?” (And that is better when there is little myeloma?)
“Sí,” María Elena said. “Exactamente. Cuando el mieloma es mucho — cuando hay miles de millones de células — el sistema inmune está sobrepasado. La lenalidomida sola no puede mantenerse al día con eso. Por eso el tratamiento de induccion fue el VRd — tres medicamentos químicos que atacan directamente a las células del mieloma. Ahora que los análisis no encuentran nada, el número de células del mieloma que quedan es el más bajo que ha estado. Ese es el momento en que el sistema inmune activado por la lenalidomida puede vigilar más efectivamente. El medicamento está trabajando en el momento en que puede hacer más.” (Yes. Exactly. When myeloma is large — when there are billions of cells — the immune system is overwhelmed. Lenalidomide alone cannot keep up with that. That is why the induction treatment was VRd — three chemical drugs that directly attack myeloma cells. Now that the tests find nothing, the number of myeloma cells that remain is the lowest it has been. That is the moment when the immune system activated by lenalidomide can surveil most effectively. The medication is working at the moment when it can do the most.)
Carlos was quiet for a moment. “¿Y los estudios qué dicen?” (And what do the studies say?)
“Hubo dos ensayos clínicos grandes — uno en Estados Unidos, uno en Francia — que compararon la lenalidomida de mantenimiento contra placebo después del trasplante. Los dos encontraron lo mismo: los pacientes que tomaron lenalidomida tuvieron más del doble de tiempo antes de que el mieloma volviera — aproximadamente 21 meses en el grupo que no tomó nada, comparado con aproximadamente 46 meses en el grupo que tomó lenalidomida. Eso es más de dos años adicionales en que el mieloma no volvió.” (There were two large clinical trials — one in the United States, one in France — that compared lenalidomide maintenance against placebo after transplant. Both found the same thing: patients who took lenalidomide had more than double the time before the myeloma came back — approximately 21 months in the group that took nothing, compared to approximately 46 months in the group that took lenalidomide. That is more than two additional years in which the myeloma did not return.)
Carlos looked at his hands. “Dos años más.” (Two more years.)
“Dos años más en que el mieloma no volvió,” María Elena confirmed. “El medicamento que está tomando todos los días no está tratando una enfermedad visible. Está retrasando el regreso de lo que no podemos ver aún.” (Two more years in which the myeloma did not return. The medication you take every day is not treating visible disease. It is delaying the return of what we cannot yet see.)
He nodded once, the way he used to nod when he agreed with a structural decision on a job site. “Bien. Sigo con la pastilla.” (Fine. I continue with the pill.)
María Elena also reviewed his side effects. The fatigue was real and she acknowledged it directly: lenalidomide fatigue is a documented side effect of immunomodulatory drugs and is not imagined. She asked about his sleep, his hydration, and whether the fatigue was worst at a particular time of day. She noted the options for supportive management and reminded him that the dose could be adjusted if fatigue became limiting — that the goal was to keep him on lenalidomide at a tolerable dose for as long as the disease remained in check, not to push through symptoms that affected his quality of life significantly. She also confirmed his thromboprophylaxis — lenalidomide significantly increases venous thromboembolic risk in myeloma patients, and he was on aspirin 81 mg daily as prophylaxis, which she reviewed.
Scenario 3: Rosa Elena Jiménez-Cruz — 63, retired school cook from Modesto, California
Rosa Elena Jiménez-Cruz is sixty-three years old, a retired school cook from Modesto who made lunch for 600 elementary school students every day for twenty-eight years. She was diagnosed with IgA kappa multiple myeloma four months before retirement, when a pathological fracture of her right fifth rib was found incidentally on a chest X-ray ordered for what she thought was a pulled muscle from carrying catering equipment. Her skeletal survey revealed seven lytic lesions: three in the thoracic spine, two in the ribs, one in the pelvis, and one in the left proximal humerus. Her M-protein was 4.2 grams per deciliter. Her bone marrow biopsy showed 62 percent clonal plasma cells with a deletion of 17p on FISH — a high-risk cytogenetic feature.
She had started on daratumumab, bortezomib, lenalidomide, and dexamethasone (Dara-VRd) eight months ago. She is responding well — her M-protein has fallen to 0.3 grams per deciliter, her lytic lesions are stable on most recent imaging, and her bone pain has largely resolved except for mild residual aching in the thoracic spine that she manages with acetaminophen.
Alongside her chemotherapy, she has been receiving monthly intravenous zoledronic acid infusions since the beginning of treatment. She had been told briefly at the start that she needed “a bone medication to protect against fractures.” She had accepted this. For eight months she has come in monthly, sat in the infusion chair for thirty minutes, and gone home. Today, at her monthly myeloma clinic visit before the infusion, she asks myeloma clinic nurse Claudia Vásquez-Herrera the question she has been sitting with for several weeks.
“Enfermera, hace ocho meses que vengo a la infusión del hueso. La semana pasada me llamaron para recordarme de la cita y mi hija me preguntó para qué era. Le dije para los huesos. Ella me preguntó que si había tenido problemas nuevos en los huesos. Yo le dije que no. Me preguntó que si el dolor ya estaba mejor. Le dije que sí. Me preguntó que entonces para qué la infusión si el dolor está mejor y el tratamiento del mieloma está funcionando.” (Nurse, for eight months I have been coming for the bone infusion. Last week they called to remind me of the appointment and my daughter asked what it was for. I told her for the bones. She asked me if there had been new bone problems. I said no. She asked me if the pain was better. I said yes. She asked me then what the infusion was for if the pain was better and the myeloma treatment was working.)
She paused. “Yo no supe qué contestarle.” (I did not know what to answer her.)
And then she added: “También mi vecina — ella toma pastillas para los huesos para la osteoporosis, no el mieloma — me dijo que tuvo una complicación con la mandíbula después de que el dentista le sacó un diente. Me asustó porque yo tengo una muela que me duele hace tiempo y el dentista dijo que hay que sacarla.” (Also my neighbor — she takes bone pills for osteoporosis, not myeloma — told me she had a jaw complication after the dentist pulled a tooth. That frightened me because I have a molar that has been hurting for a long time and the dentist said it needs to be pulled.)
Claudia recognized that Rosa had handed her two critical conversations simultaneously. The bone infusion rationale was straightforward. The dental safety question was urgent — if Rosa was planning a tooth extraction without the myeloma team’s knowledge, this needed to be addressed immediately.
She started with the mechanism of why the infusion continues.
“Le voy a explicar qué está haciendo el mieloma en sus huesos, porque eso explica por qué la infusión es importante aunque el dolor esté mejor,” she said. “El mieloma — las células plasmáticas malignas en su médula ósea — produce unas proteínas que hacen dos cosas al mismo tiempo: activan las células que destruyen el hueso y bloquean las células que lo reconstruyen. En los huesos normales, esas dos cosas trabajan juntas en un ciclo: las células que destruyen el hueso viejo hacen espacio, y las células que construyen hueso nuevo llenan ese espacio. Es un ciclo balanceado que mantiene los huesos fuertes. El mieloma rompe ese balance: la destrucción se acelera y la construcción se frena. El resultado son huecos en el hueso — las lesiones líticas que encontramos en sus radiografías — que debilitan el hueso antes de que se rompa.” (I am going to explain what myeloma is doing to your bones, because that explains why the infusion is important even though the pain is better. Myeloma — the malignant plasma cells in your bone marrow — produces proteins that do two things simultaneously: they activate the cells that destroy bone and block the cells that rebuild it. In normal bones, those two things work together in a cycle: the cells that destroy old bone make space, and the cells that build new bone fill that space. It is a balanced cycle that keeps bones strong. Myeloma breaks that balance: destruction accelerates and construction slows. The result is holes in bone — the lytic lesions we found on your X-rays — that weaken the bone before it breaks.)
Rosa nodded. She had seen the images of her lytic lesions when she was first diagnosed — the radiologist had shown her the “punched-out” areas on the film.
“¿Y el ácido zoledónico — la infusión — qué hace?” (And the zoledronic acid — the infusion — what does it do?)
“El ácido zoledónico va directo a las células que destruyen el hueso,” Claudia said. “Bloquea un proceso químico que esas células necesitan para funcionar y sobrevivir. Con ese bloqueo, las células que estaban destruyendo el hueso mueren. La destrucción del hueso se frena. El hueso no se reconstruye rápidamente — la inhibición del mieloma sobre las células que construyen hueso continúa — pero se frena el proceso activo de destrucción. Eso reduce la probabilidad de que uno de los huesos que ya están debilitados llegue al punto de romperse, o de que necesite radiación en un hueso, o de que tenga una compresión en la columna.” (Zoledronic acid goes directly to the cells that destroy bone. It blocks a chemical process those cells need to function and survive. With that block, the cells that were destroying bone die. Bone destruction slows. The bone does not rebuild rapidly — myeloma’s inhibition of the cells that build bone continues — but the active destruction process slows. That reduces the probability that one of the bones already weakened reaches the point of breaking, or that you need radiation to a bone, or that you have a compression in the spine.)
“¿Y los estudios?” Rosa asked, with the directness of someone who had learned to ask this question. (And the studies?)
“Hay un estudio grande en pacientes de mieloma que mostró que el ácido zoledónico redujo las fracturas patolbgicas, la necesidad de radiación en huesos, y la necesidad de cirugía de columna en un 40 por ciento comparado con otro medicamento menos potente. Y también mostró una mejora en la supervivencia de más de cinco meses. Eso significa que los huesos que no se rompieron, la radiaciones que no fueron necesarias, las cirugías que no hubo que hacer — todo eso corresponde a pacientes que, cuando recibían la infusión, también no tenían una fractura aún. La infusión funciona exactamente cuando no hay todavía una fractura — porque ese es el momento en que puede prevenirla.” (There is a large study in myeloma patients that showed zoledronic acid reduced pathological fractures, the need for bone radiation, and the need for spine surgery by 40 percent compared to a less potent medication. And it also showed a survival improvement of more than five months. That means the bones that did not break, the radiation that was not needed, the surgeries that did not happen — all of that corresponds to patients who, when they were receiving the infusion, also had not had a fracture yet. The infusion works exactly when there is no fracture yet — because that is when it can prevent one.)
Rosa sat with this for a moment. Then she returned to her second question — her neighbor and the jaw.
“Y lo de la mandíbula de mi vecina — y mi muela que hay que sacar — ¿tengo que preocuparme?” (And the jaw problem my neighbor had — and my molar that needs to be pulled — do I need to worry?)
Claudia was direct. “Sí — esto es algo muy importante, y me alegra mucho que me lo dijera hoy. Quiero hablarle de esto antes de que llame al dentista para esa muela.” (Yes — this is something very important, and I am very glad you told me today. I want to talk to you about this before you call the dentist about that molar.)
She explained the mechanism of medication-related osteonecrosis of the jaw (MRONJ) in plain Spanish. The zoledronic acid that goes into Rosa’s bones each month deposits with very high affinity in all bones — including the bones of the jaw. The jaw bones are different from other bones in the body because they are subject to constant mechanical stress from chewing, have very high vascularity from the periodontal tissues surrounding the teeth, and are in direct contact with the bacteria of the mouth. When a dental procedure creates a wound in the jaw bone — a tooth extraction, an implant placement, major periodontal surgery — the bone needs to remodel at the wound site to heal. In a patient whose jaw bone has been saturated with zoledronic acid, the osteoclasts that mediate that bone remodeling are suppressed. The wound may not heal properly. The bone at the wound site, deprived of adequate vascularity and exposed to oral bacteria, can become necrotic — bone that is exposed and will not heal. This is called osteonecrosis of the jaw: bone that has died and remains exposed in the mouth.
“Esto no significa que no se puede sacar la muela,” Claudia was careful to say. “Significa que no podemos simplemente dejarla ir al dentista sin coordinación con nosotros.” (This does not mean the molar cannot be pulled. It means we cannot simply let you go to the dentist without coordination with us.)
She explained what the coordination looks like. The myeloma team would need to evaluate whether the extraction could be deferred or whether the tooth was infected enough to require urgent intervention. If it required urgent intervention, the team could discuss whether a temporary pause in zoledronic acid infusions was appropriate — there is limited evidence for drug holidays but some centers practice them before invasive dental procedures. The extraction, if proceeding, would be planned with a dentist aware of the bisphosphonate use, with meticulous surgical technique to minimize bone trauma, and with appropriate post-extraction wound care. Post-operatively, the extraction site would be monitored closely for healing.
“Lo que no puede pasar es que vaya al dentista la semana que viene sin decirle que está recibiendo esta infusión,” Claudia said. “Cada dentista que la atienda — dentista de emergencia, endodoncista, peri odoncista — necesita saber que está recibiendo ácido zoledónico. Eso cambia cómo planifican cualquier procedimiento que abra el hueso de la mandíbula.” (What cannot happen is that you go to the dentist next week without telling them you are receiving this infusion. Every dentist who treats you — emergency dentist, endodontist, periodontist — needs to know you are receiving zoledronic acid. That changes how they plan any procedure that opens the jaw bone.)
“¿La limpieza está bien?” Rosa asked. (Is cleaning okay?)
“Sí — la limpieza dental, las radiografías, el tratamiento de caries sin extracción, el blanqueamiento — todo eso es seguro,” Claudia confirmed. “Es cuando el procedimiento abre el hueso de la mandíbula — extracciones, implantes, cirugía de las encías profunda — cuando hay que planificar con cuidado. La muela que le duele, si está infectada, puede que necesite tratamiento pronto. Vamos a llamar al dentista de usted hoy para coordinar cómo hacerlo de manera segura.” (Yes — dental cleaning, X-rays, cavity treatment without extraction, whitening — all of that is safe. It is when the procedure opens the jaw bone — extractions, implants, deep gum surgery — that we need to plan carefully. The molar that hurts you, if it is infected, may need treatment soon. We are going to call your dentist today to coordinate how to do it safely.)
Claudia made a note in the chart to call the dental office that afternoon, and she gave Rosa a printed card to carry that stated she was on intravenous bisphosphonate therapy and the name and phone number of the myeloma clinic for any dentist to call before an invasive procedure.
“Mi vecina no sabía que tenía que avisar,” Rosa said. (My neighbor did not know she had to warn them.)
“Eso pasa mucho,” Claudia acknowledged. “No siempre se explica esto en la misma cita donde se empieza el medicamento, porque hay muchas cosas que explicar ese día. Por eso lo estamos hablando ahora, y por eso le damos la tarjeta. La información que le acabo de dar — que necesita decirle a cada dentista — es una de las cosas más importantes que puede hacer para protegerse mientras recibe este medicamento.” (That happens a lot. This is not always explained at the same appointment where the medication is started, because there are many things to explain that day. That is why we are talking about it now, and why we give you the card. The information I just gave you — that you need to tell every dentist — is one of the most important things you can do to protect yourself while you receive this medication.)
Eight practical phrases for multiple myeloma clinic nurses
These are the eight phrases that multiple myeloma clinic nurses use most consistently when working with Spanish-speaking patients at the critical communication moments in myeloma outpatient management:
1. Explaining the MGUS-to-myeloma spectrum to a patient who cannot understand why something being watched now requires chemotherapy:
“El MGUS, el mieloma latente y el mieloma activo son el mismo tipo de célula en tres etapas distintas — la célula estaba ahí desde el principio. Lo que cambió es cuántas células hay y si ya están causando daño en los órganos. El seguimiento no era un error — era el manejo correcto para la etapa en que estaba antes.”
(MGUS, smoldering myeloma, and active myeloma are the same type of cell at three distinct stages — the cell was there from the beginning. What changed is how many cells there are and whether they are now causing organ damage. The monitoring was not a mistake — it was the correct management for the stage you were in before.)
2. Explaining why the CRAB threshold determines when treatment begins:
“El tratamiento empieza cuando las células plasmáticas han aumentado lo suficiente como para causar daño en los huesos, en los riñones, en la sangre, o en el calcio. Antes de ese punto, los estudios muestran que el tratamiento hace más daño que bien. Cuando se cruza ese punto, el balance cambia completamente.”
(Treatment starts when the plasma cells have increased enough to cause damage to bones, kidneys, blood, or calcium. Before that point, studies show treatment does more harm than good. When that point is crossed, the balance changes completely.)
3. Explaining complete response versus elimination to a patient who thinks the disease is gone:
“Respuesta completa significa que la protéina está por debajo del nivel que los análisis pueden detectar — no que las células del mieloma desaparecieron por completo. Las pruebas más sensibles aún encuentran células residuales en muchos pacientes en respuesta completa estricta. El mieloma tiene tendencia a volver, y el objetivo del tratamiento de mantenimiento es retrasar ese regreso lo más posible.”
(Complete response means the protein is below the level the tests can detect — not that the myeloma cells completely disappeared. The most sensitive tests still find residual cells in many patients in stringent complete response. Myeloma tends to return, and the goal of maintenance treatment is to delay that return as long as possible.)
4. Explaining the mechanism of lenalidomide maintenance to a patient who does not understand why he keeps taking a daily pill when tests show nothing:
“La lenalidomida no ataca el mieloma directamente — activa las células del sistema inmune que reconocen y atacan las células del mieloma residuales. Y funciona mejor cuando el mieloma está en su punto más bajo. Los estudios mostraron más del doble del tiempo hasta que el mieloma regresó en los pacientes que tomaron lenalidomida comparado con los que no tomaron nada.”
(Lenalidomide does not attack myeloma directly — it activates the immune system cells that recognize and attack residual myeloma cells. And it works best when myeloma is at its lowest point. Studies showed more than double the time until myeloma returned in patients who took lenalidomide compared to those who took nothing.)
5. Explaining why bone infusions continue when the patient has no fracture and the pain is controlled:
“El mieloma activa las células que destruyen el hueso y bloquea las que lo reconstruyen — eso sigue pasando mientras haya células del mieloma. La infusión frena esa destrucción antes de que llegue al punto de fractura. Los estudios mostraron una reducción del 40 por ciento en fracturas y cirugías de hueso en pacientes que recibieron el medicamento. El que no haya tenido fractura es exactamente lo que la infusión busca.”
(Myeloma activates the cells that destroy bone and blocks those that rebuild it — that continues as long as myeloma cells are present. The infusion slows that destruction before it reaches the fracture point. Studies showed a 40 percent reduction in fractures and bone surgeries in patients who received the medication. Not having had a fracture is exactly what the infusion seeks.)
6. Explaining the osteonecrosis of the jaw risk before the patient visits a dentist:
“El medicamento que recibe se deposita en los huesos de la mandíbula. Si un dentista hace un procedimiento que abre ese hueso — una extracción, un implante — la cicatrización puede ser más difícil y el hueso expuesto puede infectarse. Antes de cualquier procedimiento dental que no sea limpieza o radiografía, necesita llamarnos primero para coordinarlo con su dentista.”
(The medication you receive deposits in the jaw bones. If a dentist performs a procedure that opens that bone — an extraction, an implant — healing can be more difficult and the exposed bone can become infected. Before any dental procedure that is not a cleaning or X-ray, you need to call us first to coordinate with your dentist.)
7. Telling the patient what to tell every dentist going forward:
“Necesita decirle a cada dentista que la atienda — incluyendo el dentista de urgencia si tiene que ir de emergencia — que está recibiendo ácido zoledónico por infusión una vez al mes para el mieloma. Ese nombre en espanól es ácido zoledónico; el nombre de marca es Zometa. Eso cambia cómo planifica el dentista cualquier procedimiento que toque el hueso de la mandíbula.”
(You need to tell every dentist who treats you — including an emergency dentist if you have to go urgently — that you are receiving zoledronic acid by infusion once a month for myeloma. That name in Spanish is ácido zoledónico; the brand name is Zometa. That changes how the dentist plans any procedure that touches the jaw bone.)
8. Explaining minimal residual disease to a patient who asks why more sensitive tests are not always used to confirm cure:
“Existen pruebas que pueden detectar una célula del mieloma entre un millón de células normales. No hacemos esa prueba en cada visita porque es costosa y porque la decisión de continuar el tratamiento de mantenimiento no cambia con el resultado — los estudios muestran beneficio de la lenalidomida independientemente de si la prueba de residuo mínimo sale positiva o negativa. Pero la prueba sí se usa en estudios clínicos y en decisiones sobre si profundizar el tratamiento en pacientes de muy alto riesgo.”
(Tests exist that can detect one myeloma cell among one million normal cells. We do not do that test at every visit because it is costly and because the decision to continue maintenance treatment does not change with the result — studies show benefit from lenalidomide regardless of whether the minimal residual disease test is positive or negative. But the test is used in clinical studies and in decisions about deepening treatment in very high-risk patients.)
The underlying communication pattern
All three conversations in this post share a structure that multiple myeloma clinic nurses encounter across the breadth of their patient population: the patient has a model of how disease and treatment should work, that model is coherent and was learned from real medical experience, and the clinical reality of myeloma violates that model in ways that are not intuitive without understanding the mechanism.
Beatriz’s model: a treatment-free period means the disease is not dangerous; if it becomes dangerous, treatment will start quickly. What the model misses: the distinction between a monitoring decision (treatment risk exceeds benefit at low clone burden) and a management decision (treatment benefit exceeds risk at the CRAB threshold) is not intuitive from the patient’s side of the exam table. The language of “just watching” implies inactivity that the surveillance protocol does not actually reflect.
Carlos’s model: if the tests show nothing, the disease is gone; if the disease is gone, the medication is no longer needed. What the model misses: the detection threshold of standard assays is not zero, and the residual clone that falls below detection retains the capacity to re-expand. Maintenance therapy’s value is highest when target burden is lowest — the inverse of how most medications work in the patient’s experience.
Rosa’s model: medications treat symptoms or visible problems; if the symptom (bone pain) has improved and no new problem (fracture) has occurred, the medication for that symptom may not still be needed. What the model misses: bisphosphonate therapy prevents events that have not happened yet and that are mechanistically occurring below the level of clinical symptoms. And it carries a specific safety requirement — the dental coordination requirement — that is not intuitive from the medication’s indications and that requires proactive education, not reactive disclosure.
The myeloma clinic nurse who explains the mechanism — not just the directive — gives the patient the understanding that travels home with them, informs the question they ask their daughter, determines whether they call the dentist before or after the infusion appointment, and shapes whether the maintenance prescription is filled every month or sits on the pharmacy counter half the time.
In myeloma, the mechanism is the compliance.
Learn the Spanish for the next myeloma clinic encounter
ClinicaLingo builds 10-minute clinical Spanish scenarios for nurses working across oncology and hematology. The practice module includes scenarios for myeloma infusion appointments, bone marrow biopsy preparation, and treatment side-effect counseling in Spanish. The free 50-phrase clinical Spanish PDF includes the phrases most commonly needed across oncology and hematology encounters.
Related posts in the hematology-oncology library:
- Spanish for hematology-oncology inpatient nurses — chemotherapy nausea, neutropenic fever, and neutropenic precautions family education
- Spanish for hematology clinic nurses — outpatient hematology scenarios
- Spanish for bone marrow transplant nurses — transplant preparation and post-transplant education
- Spanish for infusion nurses — infusion suite scenarios across oncology and rheumatology
- Spanish for CAR-T nurses — CAR-T cell therapy education, monitoring requirements, and toxicity recognition
- Spanish for apheresis nurses — stem cell collection procedures and donor education
- Spanish for oncology nurses — foundational oncology nursing scenarios
- All clinical Spanish nursing posts